anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Circadian disruption causes glucose intolerance, cardiac fibrosis, and adipocyte dysfunction in sand rats (Psammomys obesus). Exercise intervention can improve glucose metabolism, insulin sensitivity, adipose tissue function and protect against inflammation. We investigated the influence of exercise on male P. obesus exposed to a short photoperiod (5 h light:19 h dark) and high-energy diet. Exercise reduced glucose intolerance. Exercise reduced cardiac expression of inflammatory marker Ccl2 and Bax:Bcl2 apoptosis ratio. Exercise increased heart:body weight ratio and hypertrophy marker Myh7:Myh6, yet reduced Gata4 expression. No phenotypic changes were observed in perivascular fibrosis and myocyte area. Exercise reduced visceral adipose expression of inflammatory transcription factor Rela, adipogenesis marker Ppard and browning marker Ppargc1a, but visceral adipocyte size was unaffected. Conversely, exercise reduced subcutaneous adipocyte size but did not affect any molecular mediators. Exercise increased ZT7 Bmal1 and Per2 in the suprachiasmatic nucleus and subcutaneous Per2. Our study provides new molecular insights and histological assessments on the effect of exercise on cardiac inflammation, adipose tissue dysfunction and circadian gene expression in P. obesus exposed to short photoperiod and high-energy diet. These findings have implications for the protective benefits of exercise for shift workers in order to reduce the risk of diabetes and cardiovascular disease.
Patients who have schizophrenia, schizoaffective disorder, a psychotic disorder, and are being treated with a medication called Risperidone Long Acting Injectable medication or another antipsychotic medication are candidates for the study. The purpose of the study is to find out from patients' family how they feel the medication has affected their relationship with them.The study will involve meeting with family members three times over the course of one year. The first time will be at New Hampshire Hospital (NHH) or at a community mental health center and the follow up times will be at a convenient place and time for the family member (s), in the community. We will ask them to answer questions from the Family Burden Interview and Quality of Life Questionnaire. The family will not be charged for any test that is completed solely for this study. The family will be provided a travel stipend to meet with the researchers.We do not see that there will be any risks to the family. We will be interviewing the patient's family, and they will be sharing information as to how they feel their relationship with the patient is going. All efforts will be made to keep this information confidential; however, there may be unforeseen circumstances that could lead to breaching of confidentiality. If the family expresses need for help the research staff will make recommendations for referral to a provider.
Participants in the waitlist control group received no intervention and no tracking opportunity for the duration of the trial (6 weeks), yet they had unrestricted access to treatment as usual within their companies. Upon completion of the trial, participants in the waitlist control group received access to the "Kelaa" app.
INTRODUCTION: There are some complications that can arise after surgery, like surgical site infection (SSI). In hernia repair, SSI incidence is low. Hence, the clinical practice guideline (CPG) published by the HerniaSurge Group (THG) does not recommend prophylactic antibiotics for hernia repair. Despite the unnecessary use of prophylactic antibiotics, regarding patient safety, prophylactic antibiotics can be used. However, each hospital has its own CPG and recommended antimicrobials based on the infection cases in its site. Regarding antimicrobial resistances, evaluating prophylactic antibiotics is essential to prevent increasing incidence of antimicrobial resistance cases. The aim of this study is to evaluate the use of prophylactic antibiotics in hernia inguinal cases.
MATERIALS AND METHODS: This cross-sectional analytic study used patients' medical records between 2015 to 2020. Demographic data, surgery data and the used antimicrobial data were extracted and written in case report form. Identification of risk factors for inappropriate use of prophylactic antibiotics was done using logistic regression.
RESULTS: We identified 55 inappropriate times of preoperative prophylactic antibiotic therapy cases out of 80 cases and 63 cases in post-operative antibiotics were different from the guideline. Statistical analysis did not find any factor related to inappropriate therapy time.
CONCLUSION: The misuse of prophylactic antibiotics was frequently found regarding the duration of prophylactic antibiotics in both pre- and post-surgery setting. Nonetheless, no risk factor was identified with the inappropriate use of prophylactic antibiotics.
Neuropsychiatric disorders (NPDs) are considered a potential threat to mental health. Inflammation predominantly plays a role in the pathophysiology of NPDs. Dietary patterns are widely postulated to be involved in the physiological response to inflammation. This review aims to discuss the literature on how dietary inflammatory index (DII) is related to inflammation and, consequently, NPDs. After comprehensive scrutiny in different databases, the articles that investigated the relation of DII score and various NPDs and psychological circumstances were included. The association between dietary patterns and mental disorders comprising depression, anxiety, and stress proved the role of a proinflammatory diet in these conditions' exacerbation. Aging is another condition closely associated with DII. The impact of proinflammatory and anti-inflammatory diet on sleep quality indicated related disorders like sleep latency and day dysfunctions among the different populations are in relation with the high DII score. The potential effects of genetic backgrounds, dietary patterns, and the gut microbiome on DII are discussed as well. To plan preventive or therapeutic interventions considering the DII, these factors, especially genetic variations, should be considered as there is a growing body of literature indicating the role of personalized medicine in different NPDs. To the best of our knowledge, there is a limited number of RCTs on this subject, so future research should evaluate the causality via RCTs and look for therapeutic interventions with an eye on personalized medicine using information about DII in NPDs.
This study aims to develop a model to determine whether a single, oral, weight-based dose of glucocorticoid (GC) can predict clinical and biologic response to GC s over the long term in subjects with hypereosinophilic syndrome (HES). Subjects with FIP1L1/PDGFRalpha-negative HES, who are symptomatic with eosinophil count \>1500/microL and receiving less than or equal to10 mg prednisone daily, will be enrolled. A single oral dose of prednisone (1 mg/kg rounded to the nearest 5mg) will be administered. Eosinophil count and various laboratory parameters will be assessed at 2 hours, 4 hours and 24 hours following prednisone administration (investigators will be blinded to the results of the eosinophil counts). The subjects will then begin GC therapy at 30 mg prednisone daily followed by a standardized taper. The lowest dose of GC at which symptoms and eosinophilia are controlled will be compared to the change in eosinophil count at 2, 4 and 24 hours post-challenge. Mechanisms and in vitro correlates of GC resistance will also be explored.
This study was designed as a single-center, prospective trial at King Chulalongkorn Memorial Hospital, Bangkok, Thailand between September 2022 to February 2024.

All hormone-naïve TM aged above 18 years who planned to start testosterone at Gender Health Clinic, King Chulalongkorn Memorial Hospital, Thailand were approached. All the enrolled participants will be received information about the study and written consent was obtained from all participants before the start of the study. The demographic data were recorded. Blood samples of serum estradiol, total testosterone and other laboratory investigations will be assessed including complete blood count, liver function test and lipid profiles. Then, the WHOQOLBREFTHAI questionnaire and Thai version of Female sexual function index questionnaire (FSFI) will be assessed before testosterone administration. All TM participants will be received 250 mg of testosterone enanthate intramuscularly every 4 weeks for 12 weeks. After 12 weeks of treatment, another laboratory investigations and 2 questionnaires, (WHOQOLBREFTHAI and FSFI) will be assessed again.
A delivery system for biologically active materials consisting of polysaccharide or polypeptide microspheres which bind to glycosaminoglycan receptors on cell surfaces. The delivery system can be used to localize drugs by both biochemical and physical means. In one embodiment, microspheres prepared from the polysaccharide chitosan are bound to anionic polysaccharides similar to the glycosaminoglycan receptors found on the surface of capillary endothelial cells. The microspheres were formulated to have a controlled cationic character, and had a mean diameter of 0.70 u and a magnetite content of 16% w/w. Binding to a model polysaccharide, heparin, was demonstrated in vitro. Binding to cultured cerebral capillary endothelial cells was also demonstrated.
In the PainCoach-app group, in addition to receiving the aforementioned usual care, the PainCoach app was downloaded on each patient's smartphone or tablet. Patients could use this app whenever they wanted until day 14 after surgery. They were not subjected to any different treatment compared to the control group, i.e. advice on pain management was delivered in an extra and different way, but the pain medication itself was exactly the same for both groups.
As study intervention (INT), a period of caloric restriction is set by starting the enteral nutritional support later, at POD 5. Oral caloric intake is resumed at POD 4, similarly as in the control group. This intervention results in a relative caloric defect of more than 4.000 kCal in the immediate postoperative course.
Subject in the control/Placebo/Sham arm receive 20 sessions of sham adTMS. The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
My claim is a set of "Dominant Parameters" applied to improve the traditional dual extraction process, the prior art of ethanol (alcohol) and aqueous (water) extraction for extracting phytonutrients from lnonotus obliquus, commonly known as "Chaga". Chaga is a parasitic fungus that infects birch and other trees found in northern-temperate-climate regions. Chaga has been consumed for centuries and its health benefits are well documented.  The health benefits of Chaga are largely associated with compounds that can be extracted under carefully selected conditions. Such compounds include polysaccharides, p-glucan, polyphenols, and melanin, which are water-soluble. In particular, Chaga is a source of phytosterols, such as tri-terpenes, betulin, lanosterol, lignin, and inotodiol, all of which are ethanol-soluble components. The traditional dual extraction process has not been able to provide clear and stable results to ensure the effectiveness of the programmed extraction process and provide transparent and stable quality of extracted Chaga powder product. This claim is to provide a set of "Dominant Parameters" (see DESCRIPTION) to guide the traditional dual extraction process and specify requirements in each procedure of the dual extraction process to produce a standardized component index ¨ over 50% of polysaccharides, which can be used as an indicator of the medicinal value and market value of Chaga extracted powder products for consumers to compare with other similar products on the market. My request for the grant of a patent is to apply my claims of the "Dominant Parameters" to standardize the production of dual extracted lnonotus-Obliquus (Chaga) powder for stable and transparent quality of Chaga powder product. In addition, it is more conductive to mass production.
The invention provides a cancer biomolecule marker, which belongs to the technical field of biological medicines, wherein the biomolecule marker is circular RNA circ _0082002, and the sequence of the circular RNA circ _0082002 is shown as SEQ No. 1. The cancer type comprises one of papillary thyroid cancer, nasopharyngeal carcinoma, oral cancer and ovarian cancer. The reagent for detecting circular RNA circ _0082002 is a reagent for detecting circular RNAcir _0082002 in serum. Circular RNA circ _0082002 can be used to prepare probe compositions for detecting cancer biomolecule markers. The invention screens out high-expression circular RNA circ _0082002 by applying whole transcriptome high-throughput sequencing, and the high expression of the circular RNA can regulate and control the biological function of papillary thyroid carcinoma through hsa-miR-6796-5p/ALDH1A3 signal channel; the expression of the circular RNA circ _0082002 is detected through blood examination, so that the method is more convenient and quicker, the wound is reduced, and the stable and effective early diagnosis of papillary thyroid carcinoma is realized; the circular RNAcirc _0082002 enables the target gene to be up-regulated through the sponge action with miRNA (hsa-miR-6796-5 p).
The present invention relates to foam digestive enzyme preparations and a method for producing same and, more particularly, to foam digestive enzyme preparations and a method of producing same, wherein the foam digestive enzyme preparations include foaming materials in a digestive enzyme preparation to disintegrate in the stomach and generate carbon dioxide gas so that the preparations disintegrate easily and indigestion can be quickly treated. When a person takes the digestive enzyme preparations of the present invention, the digestive enzyme preparations disintegrate in the stomach of the person to generate carbon dioxide gas. The carbon dioxide gas easily disintegrates digestion promoting materials such as digestive enzymes for rapid digestion. Peristalsis of the stomach is promoted to cause burping so that a person can quickly feel better. Moreover, by adding fragrance ingredients, the problem caused by odor from burping can be solved. When medicinal ingredients having the medical effects of promoting digestion are used as fragrance ingredients, better effects in digestion can be expected.
Epinephrine, USP is a non-selective alpha and beta-adrenergic agonist designated chemically as (R)-4-(1-Hydroxy-2-(methylamino)ethyl)benzene-1,2-diol, a white, microcrystalline powder. It has the following structural formula:

The molecular weight of epinephrine is 183.2.

Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin.   
Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is supplied as a sterile aqueous solution that is clear, colorless and nonpyrogenic. Each mL of the solution contains epinephrine (0.1 mg) as the active ingredient and the following inactive ingredients: citric acid monohydrate (3.3 mg), edetate disodium dihydrate (0.004 mg), sodium chloride (8.2 mg), sodium citrate dihydrate (1.5 mg), sodium metabisulfite, and Water for Injection. Hydrochloric acid solution is added to dissolve the active ingredient. Sodium hydroxide solution is added to adjust the pH. Nitrogen is used for blanketing protection.   
Solution must be diluted prior to intravenous use.
This is an observational cohort study. The participants will be inpatients undergoing elective CABG surgery at one tertiary medical center. Functional status (including activity of daily living, cognitive and nutritional status), symptom distress, and quality of life will be measured at multiple points: pre-surgery, day 1 to 7 post-surgery, before discharge, and 2-4 weeks after discharge. Structured questionnaire will be used to collect demographic and medical characteristics. The Barthel Index, hand-held dynamometer, 6-minute walking test, Mini-Nutritional Assessment (MNA), Mini-Mental State Examination (MMSE), Confusion Assessment Method (CAM), Symptoms Distress Scale, and Short-Form-36 Health Survey (SF-36) will be used to collect functional data and compared for changes. The trajectory of functional status, symptoms distress, and quality of life will be further analyzed. The findings will add to the literature by raising the awareness on changes of functional status, symptoms distress, and quality of life for patients undergoing elective CABG so targeted and timely intervention could be developed and planned.
1324159 Producing 7-amino-desacetoxycephalosporanic acid TOYO JOZO CO Ltd 14 March 1972 [31 May 1971] 11915/72 Heading C2A [Also in Division C3]  7 - Amino - desacetoxycephalosporanic acid having the formula is produced by N-deacylating a water-soluble salt of 7-phenylacetamido- or 7-phenoxyacetamido-desacetoxycephalosporanic acid with a deacylating enzyme produced by Bacillus megaterium B-400, FERM-P No. 748. The enzyme may be in the form of a culture filtrate of the micro-organism or a purified preparation derived from the filtrate, e.g. the enzyme adsorbed on a non-inactivating carrier (see Division C3). The preferred water-soluble salt of the cephalosporin is the Na or K salt, and the N-deacylation of the salt is effected either by incubating it insolution in a culture filtrate of the micro-organism or by passing its solution through a column of the enzyme adsorbed on an insoluble inert carrier, at pH 7-8 and 30-45‹ C. using a concentration of the salt of 0À1 to 20 mgs./ml. The 7-aminodesacetoxycephalosporin may be recovered by bringing the solution to its iso-electric point (pH 3.7), concentrating, cooling to precipitate the product and washing the precipitate with acetone and drying.
Participants in the experimental condition will receive 8 text-modules delivered as guided self-help, via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail. The treatment is a short-term psychodynamic treatment psychodynamic treatment.
The invention is a method to extract the orange flavone from the waste citrus peel and the method to refine it. It chooses the citrus peel as the raw material and gets the white-powdered product after extraction, vacuum concentration, crystal separation, purification by recrystallization and drying. The product contains large amount of pomelo peel glucoside, hesperidine, neohesperidin and other orange flavone. These health protection genes have the effects of anticancer, oxidation resistance, hypersusceptibility resistance and so on and can be widely applied to the health foods, cosmetic and so on. The production process is safe, reliable and simple. It is featured by the high extraction rate and purity of the orange flavone and is adaptable to large-scaled industrial production.
Human Experience

In clinical trials of citalopram, there were reports of citalopram overdose, including overdoses of up to 2000 mg, with no associated fatalities. During the postmarketing evaluation of citalopram, citalopram overdoses, including overdoses of up to 6000 mg, have been reported. As with other SSRIs, a fatal outcome in a patient who has taken an overdose of citalopram has been rarely reported.

Symptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose.   
Management of Overdose   
Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of citalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for citalopram. 

In managing overdosage, consider the possibility of multiple-drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.
RIPK1 is a multi-functional kinase that regulates cell death and inflammation and has been implicated in the pathogenesis of inflammatory diseases. RIPK1 acts in a kinase-dependent and kinase-independent manner to promote or suppress apoptosis and necroptosis, but the underlying mechanisms remain poorly understood. Here, we show that a mutation (R588E) disrupting the RIPK1 death domain (DD) caused perinatal lethality induced by ZBP1-mediated necroptosis. Additionally, these mice developed postnatal inflammatory pathology, which was mediated by necroptosis-independent TNFR1, TRADD, and TRIF signaling, partially requiring RIPK3. Our biochemical mechanistic studies revealed that ZBP1- and TRIF-mediated activation of RIPK3 required RIPK1 kinase activity in wild-type cells but not in Ripk1R588E/R588E cells, suggesting that DD-dependent oligomerization of RIPK1 and its interaction with FADD determine the mechanisms of RIPK3 activation by ZBP1 and TRIF. Collectively, these findings revealed a critical physiological role of DD-dependent RIPK1 signaling that is important for the regulation of tissue homeostasis and inflammation.
The invention discloses a formula of a Hui-nationality Chinese herbal red ginseng gastric cancer-treating tablet and a preparation method thereof. The medicine is a green high-tech Chinese herbal medicine for treating late gastric cancer, especially late gastric cancer which cannot be operated due to various reasons. The preparation method comprises the following steps: mixing Chinese herbal medicines such as ficus carica, solanum lyratum thumb, Chinese lobelia, radix actinidiae, turmeric, fiveleaf akebia fruit, etc. according to a certain ratio, adding water and decocting, extracting, concentrating and tabletting to obtain a traditional Chinese medicine tablet, which is used for mainly treating gastric cancer as well as treating digestive cancers such as pharyngolaryngeal cancer, esophagus cancer, cardiac carcinoma, colorectal cancer, etc. The invention has the characteristics of less medicinal odour and moderate dosage. The selected medicines are proved through pharmacology experiments of modern medicine to be capable of treating cancers.
The present invention relates to a pharmaceutical composition. The composition has a high stability and comprises an HMG-CoA reductase inhibitor (E)-3,5-dihydroxy-7-[4¦-4"-fluorophenyl-2'-cyclopro pyl-quinolin-3'-yl]-6-heptenoic acid, or its salt or ester. The composition’s stability varies depending on its pH. The pharmaceutical composition of the present invention can be produced according to any ordinary methods employable in producing peroral solid preparations. First, NK-104, a basic substance, a vehicle, a binder and a disintegrator are mixed. Next, water is added to the resulting mixture, than granulated with stirring, dried and dressed to give dry granules. Further, the granules are mixed with a lubricant, and pelletized with a pelletizer into pellets.